Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP681 for Influenza Post-exposure Prophylaxis
NCT06574503Phase 3Recruiting
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of suraxavir marboxil in influenza, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Started Dec 2024; status: recruiting.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06574503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574503.